Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Given Consensus Recommendation of “Moderate Buy” by Analysts

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) has been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $18.25.

Several research analysts have recently commented on the company. Wall Street Zen raised Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a research note on Sunday, February 8th. Morgan Stanley began coverage on shares of Adaptive Biotechnologies in a report on Monday, December 1st. They issued an “equal weight” rating and a $21.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 21st. JPMorgan Chase & Co. upped their price target on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Friday, February 6th. Finally, Guggenheim increased their price objective on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a research note on Monday, January 26th.

Adaptive Biotechnologies Stock Performance

Shares of Adaptive Biotechnologies stock opened at $16.02 on Friday. The company’s 50 day moving average price is $16.89 and its 200-day moving average price is $15.72. The stock has a market capitalization of $2.45 billion, a price-to-earnings ratio of -40.05 and a beta of 2.18. Adaptive Biotechnologies has a 52-week low of $6.26 and a 52-week high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.10. The firm had revenue of $71.68 million during the quarter, compared to analyst estimates of $59.38 million. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.Adaptive Biotechnologies’s revenue was up 51.0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.23) EPS. As a group, equities research analysts forecast that Adaptive Biotechnologies will post -0.92 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Chad M. Robins sold 124,998 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $18.44, for a total transaction of $2,304,963.12. Following the completion of the transaction, the chief executive officer owned 2,459,245 shares in the company, valued at $45,348,477.80. This trade represents a 4.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Harlan S. Robins sold 8,120 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $19.00, for a total value of $154,280.00. Following the completion of the sale, the insider owned 1,179,524 shares in the company, valued at $22,410,956. This represents a 0.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 708,000 shares of company stock valued at $12,265,389 in the last ninety days. Insiders own 6.40% of the company’s stock.

Institutional Trading of Adaptive Biotechnologies

Several hedge funds have recently made changes to their positions in the business. Ameriprise Financial Inc. increased its stake in Adaptive Biotechnologies by 84.3% during the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after acquiring an additional 2,731,648 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Adaptive Biotechnologies by 303.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock valued at $71,252,000 after purchasing an additional 3,299,635 shares during the last quarter. Westfield Capital Management Co. LP purchased a new position in shares of Adaptive Biotechnologies in the 4th quarter worth approximately $65,942,000. Geode Capital Management LLC increased its position in shares of Adaptive Biotechnologies by 3.3% during the 4th quarter. Geode Capital Management LLC now owns 3,511,855 shares of the company’s stock valued at $57,041,000 after purchasing an additional 110,825 shares during the last quarter. Finally, State Street Corp raised its holdings in Adaptive Biotechnologies by 3.3% during the 4th quarter. State Street Corp now owns 3,181,644 shares of the company’s stock valued at $51,670,000 after buying an additional 102,362 shares during the period. 99.17% of the stock is currently owned by hedge funds and other institutional investors.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.